Company Overview and News

4
Eastmain and Partners Announce Fall 2018 Exploration Program at Éléonore South Joint Venture

2018-09-11 globenewswire
TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”- TSX:ER, OTCQX:EANRF) announces the Fall 2018 Exploration Program at the Éléonore South Joint Venture Property (“ESJV”) located in James Bay, Quebec (see Figure 1).
EANRF ER AZMTF G MALRY MALRF GG MIN AZM

4
Eastmain Announces Appointment of Maura Lendon to Board of Directors

2018-07-31 globenewswire
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”- TSX:ER, OTCQX:EANRF) is pleased to announce the appointment of Maura Lendon to the Board of Directors.
EANRF HBM PPPMF ER HBM PPP P GG

4
Winter Drilling Strengthens Model for Large-Scale Intrusive Hosted Gold System at Éléonore South

2018-07-18 globenewswire
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EARNF) is pleased to announce the receipt of assay results from 32 drill holes totalling 5,449 m completed during the winter drilling campaign at the Éléonore South Joint Venture (ESJV) Property (Eastmain-Goldcorp-Azimut). This phase completes the H2/2017-H1/2018 diamond drilling program of 50 holes for a total of 9,892 m.
EANRF ER AZMTF G MALRY MALRF GG MIN AZM

4
Eastmain Resources Announces Closing of C$5.75M Bought Deal Private Placement

2018-07-05 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
EANRF ER MALRY MALRF MIN GG

4
Eastmain dépose le rapport technique de l'évaluation économique préliminaire (EEP) et la mise à jour de l'estimation des ressources minérales du gisement Eau Claire

2018-07-04 globenewswire
TORONTO, 04 juill. 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. («Eastmain» ou la «Société») – (TSX : ER, OTCQX : EANRF) annonce que la société a déposé le rapport technique 43-101 intitulé «Technical Report, Updated Mineral Resource Estimate and Preliminary Economic Assessment on the Eau Claire Gold Deposit, Clearwater Property, Québec, Canada», préparé par P&E Mining Consultants Inc. («P&E») tel qu'initialement divulgué le 23 mai 2018, sur le profil de la Société sur SEDAR (www.
EANRF ER GG

4
Eastmain Files Technical Report for Preliminary Economic Assessment and Updated Mineral Resource Estimate at the Eau Claire Project

2018-07-04 globenewswire
TORONTO, July 04, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) announces the Company has filed the 43-101 Technical Report titled, “Technical Report, Updated Mineral Resource Estimate and Preliminary Economic Assessment on the Eau Claire Gold Deposit, Clearwater Property, Quebec, Canada”, prepared by P&E Mining Consultants Inc. (“P&E”) as initially disclosed May 23rd, 2018 on the Company’s profile on SEDAR (www.
EANRF ER MALRY MALRF MIN GG

9
Eastmain Resources Announces C$5 Million Bought Deal Private Placement

2018-06-14 globenewswire
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
EANRF ER MALRY MALRF MIN GG

9
UPDATE: Eastmain Announces Robust Preliminary Economic Assessment and Updated Mineral Resource Estimate at the Eau Claire Project

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) is reissuing this morning’s press release due to minor corrections of certain footnotes as requested by one of the Qualified Persons. These changes are non-material and do not impact any quantitative figures previously released.
EANRF ER MALRY MALRF MIN GG

9
Eastmain Announces Robust Preliminary Economic Assessment and Updated Resource Estimate at the Eau Claire Project

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) is pleased to announce positive and robust results of a Preliminary Economic Assessment (“PEA”) on its 100%-owned Eau Claire Gold Project (“Eau Claire” or “Project”) located in James Bay, Québec. All figures are in Canadian dollars, unless stated.
EANRF ER MALRY MALRF MIN GG

9
Eastmain Announces Conference Call to Discuss Eau Claire PEA Expected May 23, 2018

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) expects to announce results of its Preliminary Economic Assessment (“PEA”) on its 100%-owned Eau Claire project located in James Bay, Quebec on Wednesday, May 23, 2018 before market open.
EANRF ER MALRY MALRF MIN GG

5
Eastmain Reports Voting Results from Annual General Meeting

2018-04-27 globenewswire
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) has released the voting results from its annual general meeting held Thursday April 26, 2018, in Toronto, Ontario, in accordance with Toronto Stock Exchange requirements.
EANRF ER GG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 27743M106